NCT03363347View on ClinicalTrials.gov

BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

January 1, 2008

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Thyroid Cancer
Interventions
DRUG

Redifferentiation with retinoid acid

In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.

All Listed Sponsors
lead

Heidelberg University

OTHER

NCT03363347 - BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer | Biotech Hunter | Biotech Hunter